Invivyd reports positive topline results for VYD2311 in Phase 3 COVID-19 study

Invivyd reports positive topline results for VYD2311 in Phase 3 COVID-19 study
Invivyd unveils VYD2311 Phase 3 results

Invivyd has announced positive topline results from its LIBERTY Phase 3 study of VYD2311, indicating superior safety and tolerability compared to mRNA-based COVID-19 vaccines.

The company also outlined plans to submit regulatory filings for VYD2311. Further details on approval timelines or commercial plans were not disclosed.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.